Aptinyx Inc (OQ:APTX)

Mar 30, 2020 04:01 pm ET
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2019 and...
Mar 18, 2020 04:01 pm ET
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Feb 19, 2020 08:37 am ET
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following...
Jan 30, 2020 07:07 am ET
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a publication in Movement Disorders detailing data on its novel...
Jan 14, 2020 04:01 pm ET
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 11,691,666 shares of its...
Jan 10, 2020 09:00 am ET
Aptinyx Announces Pricing of Public Offering of Common Stock
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its...
Jan 09, 2020 04:08 pm ET
Aptinyx Announces Proposed Public Offering of Common Stock
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell shares of its common stock in an...
Dec 12, 2019 07:07 am ET
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Dec 09, 2019 04:05 pm ET
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a presentation highlighting preclinical data on its novel NMDA...
Dec 05, 2019 06:58 am ET
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA...
Nov 14, 2019 07:57 am ET
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following...
Nov 12, 2019 04:01 pm ET
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2019 and highlighted...
Nov 12, 2019 07:27 am ET
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of two Phase 2 studies evaluating NYX-2925 for the...
Nov 11, 2019 08:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
Pomerantz LLP is investigating claims on behalf of investors of  Aptinyx Inc. (“Aptinyx” or the “Company”) (NASDAQ: APTX).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Nov 05, 2019 08:07 am ET
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Oct 29, 2019 01:42 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc.
Levi & Korsinsky reminds investors that it has commenced an investigation of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) concerning possible violations of federal securities laws. Aptinyx completed its initial public offering (“IPO”)...
Oct 29, 2019 01:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
Pomerantz LLP is investigating claims on behalf of investors of  Aptinyx Inc. (“Aptinyx” or the “Company”) (NASDAQ: APTX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Oct 28, 2019 06:27 pm ET
Kaskela Law LLC Announces Investigation of Aptinyx Inc. (APTX) on Behalf of Investors
Kaskela Law LLC is investigating Aptinyx Inc. (“Aptinyx” or the “Company”) (Nasdaq: APTX) on behalf of the Company’s investors.  Aptinyx investors are encouraged to contact Kaskela Law LLC at (888) 715–1740, or online at...
Oct 28, 2019 07:57 am ET
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with...
Oct 15, 2019 08:46 am ET
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced five upcoming poster presentations at the 49th Annual Meeting of...
Oct 08, 2019 09:00 pm ET
Aptinyx (APTX) Alert: Johnson Fistel Launches Investigation into Aptinyx Inc.; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, Oct. 8, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Aptinyx Inc. (NASDAQ: APTX) ("Aptinyx") for violations of federal securities laws. ...
Oct 03, 2019 09:09 pm ET
Bragar Eagel & Squire, P.C. is Investigating Aptinyx, Inc. (NYSE: APTX) on Behalf of Aptinyx Stockholders and Encourages Aptinyx Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Aptinyx, Inc. (NYSE: APTX) on behalf of Aptinyx stockholders. Our investigation concerns whether Aptinyx has violated the federal securities laws and/or engaged in other unlawful business practices.
Oct 02, 2019 06:59 pm ET
Sep 30, 2019 07:03 am ET
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief business...
Sep 26, 2019 08:07 am ET
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that preclinical data from the company’s novel NMDA receptor...
Sep 23, 2019 05:27 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) for violations of securities laws. If you are a...
Sep 16, 2019 05:06 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ:
Sep 04, 2019 09:21 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ:
Sep 04, 2019 07:27 am ET
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Rachel Sherman, M.D., M.P.H., former principal...
Aug 21, 2019 08:33 am ET
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor...
Aug 12, 2019 06:33 am ET
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2019 and recent...
Aug 06, 2019 08:33 am ET
Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and chief executive officer,...
Aug 05, 2019 08:03 am ET
Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Jul 12, 2019 08:30 am ET
Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Joseph Moskal, Ph.D., the company’s chief scientific officer,...
Jun 26, 2019 08:03 am ET
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor...
Jun 18, 2019 08:27 am ET
Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief business...
Jun 10, 2019 07:23 am ET
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive top-line results from a 23-patient, single-blind,...
May 14, 2019 06:27 am ET
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2019 and announced recent...
May 07, 2019 07:23 am ET
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Henry O. Gosebruch to its board of directors,...
May 06, 2019 07:27 am ET
Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Apr 30, 2019 07:27 am ET
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported positive results from a Phase 1 study of its novel NMDA receptor...
Apr 18, 2019 07:27 am ET
Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today highlighted detailed analysis of the recently completed Phase 2 study of its...
Apr 09, 2019 07:10 am ET
Market Trends Toward New Normal in Aclaris Therapeutics, Wingstop, South Jersey Industries, LiveRamp, Garrison Capital, and Aptinyx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), Wingstop Inc. (NASDAQ:WING),...
Apr 04, 2019 08:00 am ET
Aptinyx to Present at 18th Annual Needham Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Apr 03, 2019 07:27 am ET
Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical data on its novel NMDA receptor modulator,...
Mar 28, 2019 07:07 am ET
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detailed results...
Mar 22, 2019 07:27 am ET
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations highlighting preclinical data on its novel...
Mar 21, 2019 07:07 am ET
Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2018 and...
Mar 14, 2019 08:00 am ET
Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Mar 06, 2019 08:00 am ET
Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Feb 22, 2019 08:00 am ET
Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in...
Feb 19, 2019 07:27 am ET
Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has dosed the first patient in a Phase 2 study of NYX-783...
Jan 16, 2019 07:27 am ET
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced top-line results from a Phase 2 clinical study of NYX-2925 in...
Jan 02, 2019 08:07 am ET
Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Dec 11, 2018 08:27 am ET
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced two upcoming poster presentations highlighting preclinical data on...
Dec 05, 2018 08:07 am ET
Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in...
Dec 03, 2018 07:27 am ET
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results from an interim analysis of an exploratory study...
Nov 21, 2018 07:25 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atlantic American Corporation (NASDAQ:AAME), Titan Medical Inc....
Nov 13, 2018 07:27 am ET
Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and business highlights for the third quarter ended...
Nov 12, 2018 07:07 am ET
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that exploratory clinical studies of its novel NMDA receptor...
Nov 01, 2018 07:27 am ET
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced enrollment completion for the company’s Phase 2 study of NYX-2925...
Oct 29, 2018 08:07 am ET
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced four upcoming poster presentations highlighting preclinical data on...
Sep 25, 2018 04:01 pm ET
Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the Cantor...
Sep 14, 2018 08:07 am ET
Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of two posters highlighting preclinical data on...
Aug 21, 2018 06:35 am ET
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a poster presentation at the Military Health System Research...
Aug 14, 2018 06:27 am ET
Aptinyx Reports Second Quarter 2018 Financial and Business Results
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and business highlights for the second quarter...
Aug 02, 2018 08:00 am ET
Aptinyx Initiates Phase 1 Study of NYX-458
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced initiation of Phase 1 clinical development of NYX-458, its third...
Jun 25, 2018 05:18 pm ET
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
EVANSTON, Ill., June 25, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders, today announced the closing of its initial public offering of 7,359,998 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 959,999 additional shares. The gross proceeds from the offering are expected to be $117.8 mil...
Jun 20, 2018 08:41 pm ET
Aptinyx Announces Pricing of Initial Public Offering
EVANSTON, Ill., June 20, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the pricing of its initial public offering of 6,399,999 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aptinyx. In addition, Aptinyx has granted the underwriters a 30-day option to purchase 959,999 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions....